Ratings Galapagos NV

Equities

GLPG

BE0003818359

Real-time Euronext Amsterdam Other stock markets 03:37:45 2024-04-18 am EDT			5-day change	1st Jan Change
27.2 ^EUR	-0.66%		-5.75%	-26.47%

Apr. 08	Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024	CI
Mar. 28	Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says	MT

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company appears to be poorly valued given its net asset value.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's earnings growth outlook lacks momentum and is a weakness.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Over the past twelve months, analysts' opinions have been revised negatively.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
GALAPAGOS NV	-26.47%	1.92B	B
IQVIA HOLDINGS INC.	-1.78%	41.36B	B
LONZA GROUP AG	+45.72%	41.3B	A
MODERNA, INC.	+4.01%	39.61B	B-
CELLTRION, INC.	-15.14%	25.62B	C
ICON PUBLIC LIMITED COMPANY	+3.16%	24.09B	B-
ALNYLAM PHARMACEUTICALS, INC.	-24.08%	18.38B	B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.82B	C+
MEDPACE HOLDINGS, INC.	+24.76%	11.85B	C+
UNITED THERAPEUTICS CORPORATION	+7.01%	11.07B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes